Visceral leishmaniosis in immunocompromised host: an update and literature review

References

• Aronson N, Herwaldt BL, Pearson R, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of Leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America [IDSA] and the American Society of Tropical Medicine and Hygiene [ASTMH]. Clin Infect Dis. 2016;63:1539–57.10.1093/cid/ciw742
   PubMed Web of Science ®Google Scholar
• Alvar J, Velez ID, Bern C, Desjeux P, Cano J, Jannin J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671.10.1371/journal.pone.0035671
   PubMed Web of Science ®Google Scholar
• Herrador Z, Gherasim A, Jimenez BC, Granados M, Sn Martin JV, Aparicio P. Epidemiological changes in leishmaniasis in Spain according to hospitalization-based records, 1997–2011: raising awareness towards leishmaniasis in Non-HIV patients. PloS Negl Trop Dis. 2015;9:e0003594.10.1371/journal.pntd.0003594
   PubMed Web of Science ®Google Scholar
• Belo VS, Werneck GL, Barbosa DS, Simões TC, Nascimento BWL, da Silva SS, et al. Factors associated with visceral leishmaniasis in the Americas: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2013;7:e2182.10.1371/journal.pntd.0002182
   PubMed Web of Science ®Google Scholar
• van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect. 2014;20:286–99.10.1111/1469-0691.12556
   PubMed Web of Science ®Google Scholar
• van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am. 2012;26:309–22.10.1016/j.idc.2012.03.005
   PubMed Web of Science ®Google Scholar
• Lindoso JA, Cota GF, da Cruz AM, Goto H, Maia-Elkhoury AN, Romero GA, et al. Visceral leishmaniasis and HIV coinfection in Latin America. PLoS Negl Trop Dis. 2014;8:e3136.10.1371/journal.pntd.0003136
   PubMed Web of Science ®Google Scholar
• World Health Organization. Strategic framework for leishmaniasis control in the WHO European Region 2014‒2020. [cited 2017 Mar 14]. Available from: http://www.euro.who.int/data/assets/pdf_file/0017/245330/Strategic-framework-for-leishmaniasis-control-in-the-WHO-European-Region-20142020.pdf?ua=1
   Google Scholar
• Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol. 2011;9:604–15.10.1038/nrmicro2608
   PubMed Web of Science ®Google Scholar
• Yimer M, Abera B, Mulu W, Zenebe Y, Bezabih B. Proportion of visceral leishmaniasis and human immune deficiency virus co- infection among clinically confirmed visceral leishmaniasis patients at the endemic foci of the Amhara National Regional State, northwest Ethiopia. Am J Biomed Life Sci. 2014;2:1–7.10.11648/j.ajbls.20140201.11
   Google Scholar
• Burza S, Mahajan R, Sanz MG, Sunyoto T, Kumar R, Mitra G, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis. 2014;59:552–5.10.1093/cid/ciu333
   PubMed Web of Science ®Google Scholar
• Monge-Maillo B, Norman FF, Cruz I, Alvar J, López-Vélez R. Visceral leishmaniasis and HIV coinfection in the Mediterranean Region. PLoS Negl Trop Dis. 2014;8:e3021.10.1371/journal.pntd.0003021
   PubMed Web of Science ®Google Scholar
• Ena J, Pasquau F, del Mar López-Perezagua M, Martinez-Peinado C, Arjona F. Screening for subclinical Leishmania infection in HIV-infected patients living in eastern Spain. Pathog Glob Health. 2014;108:356–61.10.1179/2047773214Y.0000000164
   PubMed Web of Science ®Google Scholar
• Gramiccia M, Scalone A, Di Muccio T, Orsini S, Fiorentini E, Gradoni L. The burden of visceral leishmaniasis in Italy from 1982 to 2012: a retrospective analysis of the multi-annual epidemic that occurred from 1989 to 2009. Euro Surveill. 1982;2013(18):20535.
   Google Scholar
• Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The Relationship between Leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21:334–59.10.1128/CMR.00061-07
   PubMed Web of Science ®Google Scholar
• Okwor I, Uzonna JE. The immunology of Leishmania/HIV co-infection. Immunol Res. 2013;56:163–71.10.1007/s12026-013-8389-8
   PubMed Web of Science ®Google Scholar
• Pineda JA, Martín-Sánchez J, Macías J, Morillas F. Leishmania spp. infection in injecting drug users. Lancet. 2002;360:950–1.10.1016/S0140-6736(02)11056-7
   PubMed Web of Science ®Google Scholar
• Badaró R, Gonçalves LO, Gois LL, Maia ZP, Benson C, Grassi MF. Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients: a literature review. J Int Assoc Provid AIDS Care. 2015;14:402–7.10.1177/2325957414555225
   PubMedGoogle Scholar
• Pagliano P, Rossi M, Rescigno C, Altieri S, Coppola MG, Gramiccia M, et al. Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases. J Antimicrob Chemother. 2003;52:264–8.10.1093/jac/dkg340
   PubMed Web of Science ®Google Scholar
• Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8:191–9.10.1016/S1473-3099(08)70043-4
   PubMed Web of Science ®Google Scholar
• Hadjipetrou A, Anyfantakis D, Gkogkou A, Palla K, Lagoudaki E, Milonaki T, et al. Visceral leishmaniasis in a psoriatic arthritis patient treated with methotrexate. Infez Med. 2014;22:230–5.
   PubMedGoogle Scholar
• Zanger P, Kötter I, Kremsner PG, Gabrysch S. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect. 2012;18:670–6.10.1111/j.1469-0691.2011.03674.x
   PubMed Web of Science ®Google Scholar
• Pagliano P, Ascione T, Boccia G, De Caro F, Esposito S. Listeria monocytogenes meningitis in the elderly: epidemiological, clinical and therapeutic findings. Infez Med. 2016;24:105–11.
   PubMedGoogle Scholar
• Guedes-Barbosa LS, Pereira da Costa I, Fernandes V, Henrique da Mota LM, de Menezes I, Aaron Scheinberg M. Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases). Semin Arthritis Rheum. 2013;43:152-7.
   PubMed Web of Science ®Google Scholar
• Pagliano P, Attanasio V, Rossi M, Ascione T, Fraganza F, Di Sarno R, et al. Pneumococcal meningitis in cirrhotics: distinctive findings of presentation and outcome. J Infect. 2012;65:577–9.10.1016/j.jinf.2012.08.019
   PubMed Web of Science ®Google Scholar
• Ascione T, Pagliano P, Balato G, Mariconda M, Rotondo R, Esposito S. Oral therapy, microbiological findings, and comorbidity influence the outcome of prosthetic joint infections undergoing 2-stage exchange. J. Arthroplasty. Forthcoming 2017. doi:10.1016/j.arth.2017.02.057
   Google Scholar
• Pagliano P, Carannante N, Gramiccia M, Ascione T, Stornaiuolo G, Gradoni L, et al. Visceral leishmaniasis causes fever and decompensation in patients with cirrhosis. Gut. 2007;56:893–4.10.1136/gut.2007.119495
   PubMed Web of Science ®Google Scholar
• Saporito L, Giammanco GM, De Grazia S, Colomba C. Visceral leishmaniasis: host–parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host. Int J Infect Dis. 2013;17:e572–e576.10.1016/j.ijid.2012.12.024
   PubMed Web of Science ®Google Scholar
• Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol. 2008;10:1221–34.10.1111/j.1462-5822.2008.01146.x
   PubMed Web of Science ®Google Scholar
• Esposito V, Verdina A, Manente L, Spugnini EP, Viglietti R, Parrella R, et al. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol. 2013;228(3):640–5.10.1002/jcp.v228.3
   PubMed Web of Science ®Google Scholar
• Andreni G, Lodge R, Richard D, Tremblay MJ. Mechanisms of interaction between protozoan parasites and HIV. Curr Opin HIV AIDS. 2012;7:276–82.
   PubMed Web of Science ®Google Scholar
• Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J. Visceral leishmaniasis and HIV coinfection in East Africa. PLOS Negl Trop Dis. 2014;8:e2869.10.1371/journal.pntd.0002869
   PubMed Web of Science ®Google Scholar
• Pittalis S, Nicastri E, Spinazzola F, Ghirga P, De Marco M, Paglia MG, et al. Leishmania infantum leishmaniasis in corticosteroid-treated patients. BMC Infect Dis. 2003;6:177.
   Web of Science ®Google Scholar
• Rousseau D, Suffia I, Ferrua B, Philip P, Le Fichoux Y, Kubar JL. Prolonged administration of dexamethasone induces limited reactivation of visceral leishmaniasis in chronically infected BALB/c mice. Eur Cytokine Netw. 1998;9:655–61.
   PubMed Web of Science ®Google Scholar
• Català A, Roé E, Dalmau J, Pomar V, Muñoz C, Yelamos O, et al. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology. 2015;230:204–7.10.1159/000370238
   PubMed Web of Science ®Google Scholar
• Fernández-Guerrero ML, Robles P, Rivas P, Mójer F, Muñíz G, de Górgolas M. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop. 2004;90:11–6.10.1016/j.actatropica.2003.09.009
   PubMed Web of Science ®Google Scholar
• Pagliano P, Ascione T, Di Flumeri G, Boccia G, De Caro F. Visceral leishmaniasis in immunocompromised: diagnostic and therapeutic approach and evaluation of the recently released IDSA guidelines. Infez Med. 2016;24:265–71.
   PubMedGoogle Scholar
• Diro E, van Griensven J, Mohammed R, Colebunders R, Asefa M, Hailu A, et al. Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings. Lancet Infect Dis. 2015;15:122–9.10.1016/S1473-3099(14)70833-3
   PubMed Web of Science ®Google Scholar
• Nigro L, Montineri A, La Rosa R, Zuccarello M, Iacobello C, Vinci C, et al. Visceral leishmaniasis and HIV co-infection: a rare case of pulmonary and oral localization. Infez Med. 2016;24:265–71.
   PubMedGoogle Scholar
• Bosch RJ, Rodrigo AB, Sanchez C, de Galvez MV, Herrera E. Presence of Leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis. Int J Dermatol. 2002;41:670–675.10.1046/j.1365-4362.2002.01610.x
   PubMed Web of Science ®Google Scholar
• Cota GF, de Sousa MR, Demarqui FN, Rabello A. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis. 2012;6:e1665.10.1371/journal.pntd.0001665
   PubMed Web of Science ®Google Scholar
• Pérez-Jacoiste Asín MA, Carrasco-Antón N, Fernández-Ruiz M, San Juan R, Alonso-Moralejo R, González E, et al. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain. Transpl Infect Dis. 2017;19:e12623.10.1111/tid.2017.19.issue-1
   Web of Science ®Google Scholar
• Hendrickx S, Beyers J, Mondelaers A, Eberhardt E, Lachaud L, Delputte P, et al. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum. J Antimicrob Chemother. 2016;71:1914–21.10.1093/jac/dkw096
   PubMed Web of Science ®Google Scholar
• Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother. 2003;52:464–8.10.1093/jac/dkg356
   PubMed Web of Science ®Google Scholar
• Cota GF, de Sousa MR, Fereguetti TO, Rabello A. Efficacy of anti-Leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLOS Negl Trop Dis. 2013;7:e2195.10.1371/journal.pntd.0002195
   PubMed Web of Science ®Google Scholar
• Mastroianni A. Liposomal Amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS. Infez Med. 2004;12:197–204.
   PubMedGoogle Scholar
• Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B [AmBisome]. PLOS Negl Trop Dis. 2014;8:e3053.10.1371/journal.pntd.0003053
   PubMed Web of Science ®Google Scholar
• Pagliano P, Attanasio V, Rossi M, Carleo MA, Carannante N, Ascione T, et al. Listeria monocytogenes meningitis in the elderly: distinctive characteristics of the clinical and laboratory presentation. J Infect. 2012;71:134–6.
   Web of Science ®Google Scholar
• Pagliano P, Costantini S, Gradoni L, Faella FS, Spasiano A, Mascarella G, et al. Distinguishing visceral leishmaniasis from intolerance to pegylated interferon-alpha in a thalassemic splenectomized patient treated for chronic hepatitis C. Am J Trop Med Hyg. 2008;79:9–11.
   PubMed Web of Science ®Google Scholar